Express News | Shanghai Pharmaceutical: It is intended to issue various short-term debt financing products and medium- to long-term debt financing products with a balance equal to RMB 15 billion.
Shanghai Pharmaceutical (02607) plans to apply for the issuance of various short-term debt financing products and medium- to long-term debt financing products
Shanghai Pharmaceutical (02607) issued an announcement. The company plans to apply for a distribution balance of not more than RMB 15 billion worth of all types...
Express News | Shanghai Pharmaceutical: Net profit from mother in the first quarter was 1,542 billion yuan, up 1.62% year-on-year
上海醫藥:2024年第一季度報告
上海醫藥:2023 年年報
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
Featured announcements | Zijin Mining's Q1 net profit increased 15% year over year; Bubble Mart's overseas revenue increased by more than 240% in the first quarter
China Mobile's Q1 net profit increased 5.5% year over year to 29.6 billion yuan; Chabaidao's IPO was priced at HK$17.50 per share, with a net raise of HK$2,463 billion.
Express News | Shanghai Pharmaceutical: WST03 preparation clinical trial application accepted
Damo: Target price for Shanghai Pharmaceutical (02607) “gain” rating reduced to HK$17
DamocaSea Pharmaceuticals (02607) lowered its 2024-2030 profit forecast by 2%-9%.
Shanghai Pharmaceutical (02607.HK) held a board meeting on April 26 to approve the first quarter results
Gelonghui, April 16 | Shanghai Pharmaceutical (02607.HK) announced that the board of directors meeting will be held on April 26, 2024 (Friday) to approve (among other things) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
上海醫藥:董事會會議通告
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Southwest Securities released a research report on April 11 stating that it gave Shanghai Pharmaceutical (601607.SH) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) pharmaceutical bu
Southwest Securities released a research report on April 11 stating that it gave Shanghai Pharmaceutical (601607.SH) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) pharmaceutical business: accelerating the layout of commercial network coverage and continuing to consolidate its leading position; 3) pharmaceutical industry: continuing to promote the cultivation strategy of large varieties of traditional Chinese medicine around the big variety strategy; 4) the innovation pipeline has entered the harvest period, and the market potential is huge. (Mainichi Keizai Shimbun)
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Shanghai Pharmaceutical (601607): 23 years of steady revenue growth, and the innovation pipeline has entered a harvest period
Event: The company released its 2023 annual report. In 2023, the company achieved revenue of 26.3 billion yuan (+12.2%); net profit attributable to mother was 3.77 billion yuan (-32.9%); net profit to mother after deducting one-time special profit and loss was 49 billion yuan
Research Report Nuggets丨Zheshang Securities: Shanghai Pharmaceuticals' 23-year profits are under pressure in the short term, optimistic about the 24-year inflection point
According to the Zheshang Securities Research Report, Shanghai Pharmaceutical (601607.SH)'s revenue grew steadily in 2023, and profits were under pressure in the short term. It is optimistic about the 24-year inflection point and maintains an “gain” rating. The company continued to make efforts in innovative distribution business, deepened sales cooperation with overseas MNC, and achieved a higher growth rate than the sector as a whole. In 2023, the total number of imported products added by the company reached 29, and the CSO business revenue was 2.9 billion yuan, or about 50% by YOY. Looking ahead, the bank is optimistic about the continued and rapid expansion of the company's commercial side in high-value-added and emerging distribution businesses such as innovative distribution and non-pharmaceutical distribution, and the company is optimistic about the north and south
Express News | Zheshang Securities: Shanghai Pharmaceutical's profit in 23 years is under pressure in the short term, optimistic about the 24-year inflection point
Express News | Shanghai Pharmaceutical: Rabeprazole sodium enteric tablets passed generic drug consistency evaluation
Featured announcements | Shunyu Optics mobile phone lens shipments increased by more than 30%; China Life Insurance's original premium revenue increased by 3.2%
Hang Seng Bank: It plans to repurchase no more than HK$3 billion of shares. The automatic share repurchase plan will run from April 10, 2024 to September 9, 2024; Shandong Gold: A wholly-owned subsidiary in Hong Kong plans to apply for a revolving loan of US$30 million from Bank of Communications (Hong Kong).
Shanghai Pharmaceutical (601607): Under short-term pressure, optimistic about the 24-year inflection point
Key investment results: steady growth in revenue in 2023, short-term pressure on profits 2023 performance: revenue of 26,295 billion yuan, yoy +12.21%; when split, the company's distribution sector revenue was 2337.60
No Data